Colby Pharmaceutical
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Colby Pharmaceutical - overview
Established
2004
Location
San Jose, CA, US
Primary Industry
Pharmaceuticals
About
Colby Pharmaceutical develops innovative therapeutic drugs focused on inflammatory conditions, offering effective alternatives to existing medications, and targeting significant unmet medical needs in global markets. Colby Pharmaceutical specializes in creating advanced therapeutic solutions for inflammatory conditions. Founded in 2004 in San Jose, US, the company has operated independently without notable pivots or changes to its core mission. David Zarling currently serves as the CEO, guiding the company's strategic direction since its inception.
Colby Pharmaceutical Company specializes in the development of innovative therapeutic drugs aimed at addressing inflammatory conditions. Their core product offerings are designed to be safer, more effective, and cost-efficient alternatives to existing medications in the market. These products aim to provide patients with faster acting, longer-lasting solutions that can spare doses while enhancing overall efficacy. The company focuses on large global markets where there is a significant unmet medical need, targeting various inflammatory conditions that affect diverse populations.
End users include patients suffering from chronic inflammatory diseases, healthcare providers, and institutions seeking advanced treatment options. Markets served may include North America, Europe, and parts of Asia, where demand for effective anti-inflammatory therapies continues to grow. Colby Pharmaceutical Company operates through a structured revenue model that includes B2B transactions with healthcare providers and institutions, as well as direct-to-consumer sales of its pharmaceutical products. Transactions revolve around partnerships with wholesalers and retailers, facilitating distribution to end users.
The revenue is primarily generated through the sale of their flagship pharmaceutical products, which cater to various inflammatory conditions. Pricing plans are structured to reflect the value and efficacy of the treatments offered, providing a framework for sustainable revenue generation. This business model aligns with the company's mission to deliver effective therapeutic solutions while catering to the financial dynamics of the healthcare market.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals
Website
www.colbypharma.com
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.